Drug Target Identification Using Side-Effect Similarity
Open accessThe DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
Targets for drugs have so far been predicted on the basis of molecular or cellular features, for example, by exploiting similarity in chemical structure or in activity across cell lines. We used phenotypic side-effect similarities to infer whether two drugs share a target. Applied to 746 marketed drugs, a network of 1018 side effect–driven drug-drug relations became apparent, 261 of which are formed by chemically dissimilar drugs from different therapeutic indications. We experimentally tested 20 of these unexpected drug-drug relations and validated 13 implied drug-target relations by in vitro binding assays, of which 11 reveal inhibition constants equal to less than 10 micromolar. Nine of these were tested and confirmed in cell assays, documenting the feasibility of using phenotypic information to infer molecular interactions and hinting at new uses of marketed drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The work of Campillios et al. previously suggested the similarity of two drugs’ side effect profiles is positively correlated with the probability that these drugs share a common target28.”
From OnSIDES database: Extracting adverse drug events from drug labels using natural language processing models (2025) · cites this paper as [28]
Citations
Cites
The unified medical language system (UMLS): integrating biomedical terminology
Bodenreider, O. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh061 · Cited by 4,356
Docking and scoring in virtual screening for drug discovery: methods and applications
Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1549 · Cited by 4,150
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Gohlke, H., & Klebe, G. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20020802)41:15<2644::aid-anie2644>3.0.co;2-o · Cited by 843
Global mapping of pharmacological space
Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S., & Hopkins, A. L. (2006) · Nature Biotechnology · doi:10.1038/nbt1228 · Cited by 811
Do Structurally Similar Molecules Have Similar Biological Activity?
Martin, Y. C., Kofron, J. L., & Traphagen, L. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020155c · Cited by 806
SuperTarget and Matador: resources for exploring drug-target relationships
Gunther, S., Kuhn, M., Dunkel, M., Campillos, M., Senger, C., Petsalaki, E., Ahmed, J., Urdiales, E. G., Gewiess, A., Jensen, L. J., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm862 · Cited by 647
Self-citation
Research works printed but not linked: 3
- J. Blagg, Annu. Rep. Med. Chem.41, 353 (2006).
- S. Guntheret al., Nucleic Acids Res.36, D919 (2008).
- C. M. Krejsaet al., Curr. Opin. Drug Discov. Dev.6, 470 (2003).
Cited by
Items 301–400 of 1,000
Systematic exploration of cell morphological phenotypes associated with a transcriptomic query
Nassiri, I., & McCall, M. N. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky626 · Cited by 61
“Similar transcriptomic profiles can be used to reveal shared mechanism of action and phenotypic impact between compounds (15–17) because compounds with similar gene expression signatures tend to interact with similar protein targets (18).”
BackgroundDrug-target interaction prediction using semi-bipartite graph model and deep learning
Manoochehri, H. E., & Nourani, M. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-3518-6 · Cited by 71
Cichonska, A., Rousu, J., & Aittokallio, T. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1096926 · Cited by 65
“, where the authors used phenotypic side-effect similarities in the inference of compound--target connections, several of which were tested and confirmed with in vivo assays [47].”
BackgroundShigemizu, D., Hu, Z., Hung, J., Huang, C. L., Wang, Y., & DeLisi, C. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002347 · Cited by 70
“networks, and side-effect similarity [13], which diminishes the effectiveness of de novo drug discovery.”
BackgroundResultDrug Effect Prediction by Polypharmacology-Based Interaction Profiling
Simon, Z., Peragovics, Á., Vigh-Smeller, M., Csukly, G., Tombor, L., Yang, Z., Zahoránszky-Köhalmi, G., Végner, L., Jelinek, B., Hári, P., et al. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci2002022 · Cited by 68
Nanomaterials for Biosensors and Implantable Biodevices
Luz, R. A. S., Iost, R. M., & Crespilho, F. N. (2012) · Springer eBooks · doi:10.1007/978-3-642-29250-7_2 · Cited by 79
Integrative relational machine-learning for understanding drug side-effect profiles
Bresso, E., Grisoni, R., Marchetti, G., Karaboga, A. S., Souchet, M., Devignes, M., & Smaïl‐Tabbone, M. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-207 · Cited by 80
“[4] used a corpus-based side-effect similarity approach to show that pairs of drugs sharing similar side effects can have common targets.”
BackgroundMethodPredicting drug side-effects by chemical systems biology
Tatonetti, N. P., Liu, T., & Altman, R. B. (2009) · Genome biology · doi:10.1186/gb-2009-10-9-238 · Cited by 71
MeSHDD: Literature-based drug-drug similarity for drug repositioning
Brown, A. S., & Patel, C. J. (2017) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocw142 · Cited by 63
“10 Recently, however, a number of methods have been developed to utilize large-scale biomedical data from indirect sources, such as side effect profiles 11,12 and medical records data.”
A unified frame of predicting side effects of drugs by using linear neighborhood similarity
Zhang, W., Yue, X., Liu, F., Chen, Y., Tu, S., & Zhang, X. (2017) · BMC Systems Biology · doi:10.1186/s12918-017-0477-2 · Cited by 68
Maghsoudi, S., Shahraki, B. T., Rameh, F., Nazarabi, M., Fatahi, Y., Akhavan, O., Rabiee, M., Mostafavi, E., Lima, E. C., Saeb, M. R., et al. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14136 · Cited by 70
New Uses for Old Drugs: Pharmacophore‐Based Screening for the Discovery of P‐Glycoprotein Inhibitors
Palmeira, A., Rodrigues, F., Sousa, E., Pinto, M., Vasconcelos, M. H., & Fernandes, M. X. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01089.x · Cited by 63
“Additionally, side-effects are a complex phenomenon that occur in a variety of molecular scenarios, the most important of which being the direct interaction with other protein targets such as, for instance, P-gp (17,18).”
BackgroundPharmacological Mechanism-Based Drug Safety Assessment and Prediction
Abernethy, D. R., Woodcock, J., & Lesko, L. J. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.55 · Cited by 64
TM6SF2 and MAC30, new enzyme homologs in sterol metabolism and common metabolic disease
Sanchez-Pulido, L., & Ponting, C. P. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00439 · Cited by 63
“Drug crossreactivity among homologous proteins frequently underlies undesired pleiotropic effects (Searls, 2003; Campillos et al., 2008). www.frontiersin.org December 2014 | Volume 5 | Article 439 | 5 Tamoxifen is a known inhibitor of EBP (Moebius et al., 1998; Kedjouar et al., 2004; de Medina et…”
BackgroundHuang, L., Wu, X., & Chen, J. Y. (2012) · PROTEOMICS · doi:10.1002/pmic.201200337 · Cited by 71
“[4] successfully combined drug chemical similarity and side effect similarity for drug target prediction through building drug–drug similarity networks.”
BackgroundStructural Insights into the Molecular Basis of the Ligand Promiscuity
Sturm, N., Desaphy, J., Quinn, R. J., Rognan, D., & Kellenberger, E. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300196g · Cited by 67
Laenen, G., Thorrez, L., Börnigen, D., & Moreau, Y. (2013) · Molecular BioSystems · doi:10.1039/c3mb25438k · Cited by 71
Established and Emerging Trends in Computational Drug Discovery in the Structural Genomics Era
Taboureau, O., Baell, J. B., Fernández‐Recio, J., & Villoutreix, B. O. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.007 · Cited by 69
Vesterinen, H. M., Connick, P., Irvine, C., Sena, E. S., Egan, K. J., Carmichael, G. G., Tariq, A., Pavitt, S. H., Chataway, J., Macleod, M. R., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117705 · Cited by 66
Computational Drug Repositioning: Current Progress and Challenges
Ko, Y. (2020) · Applied Sciences · doi:10.3390/app10155076 · Cited by 67
“It is also possible that the adverse effect profile of a specific drug is similar with the expression profile of a particular disease, which gives a critical clue for shared physiology between a drug and a disease [49].”
BackgroundAudouze, K., Juncker, A. S., Roque, F. S., Krysiak-Baltyn, K., Weinhold, N., Taboureau, O., Jensen, T. S., & Brunak, S. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000788 · Cited by 63
“candidates for drugs, using structural chemical similarity [7–10].”
MethodMahmud, S., Chen, W., Jahan, H., Liu, Y., Sujan, N. I., & Ahmad, S. (2019) · IEEE Access · doi:10.1109/access.2019.2910277 · Cited by 64
“[22] adopted similarities of phenotypic sideeffects to infer molecular functions from drugs and targets.”
BackgroundDrug-pathway association prediction: from experimental results to computational models
Wang, C.-C., Zhao, Y., & Chen, X. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa061 · Cited by 66
Recent Trends and Observations in the Design of High-Quality Screening Collections
Renner, S., Popov, M., Schuffenhauer, A., Roth, H.-J., Breitenstein, W., Marzinzik, A., Lewis, I., Krastel, P., Nigsch, F., Jenkins, J., et al. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.15 · Cited by 60
Network-Based Analysis and Characterization of Adverse Drug–Drug Interactions
Takarabe, M., Shigemizu, D., Kotera, M., Goto, S., & Kanehisa, M. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200367w · Cited by 59
3D pharmacophores as tools for activity profiling
Schuster, D. (2010) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2010.11.006 · Cited by 64
Drug Repurposing: Claiming the Full Benefit from Drug Development
Kort, E. J., & Jovinge, S. V. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01484-5 · Cited by 63
“Traditional drug design does not address these complex causes and effects which prior to the advent of high-throughput transcriptional profiling platforms would have been intractable, but with the development of microarray transcriptomic profiling followed by next-generation sequencing approaches, it is now possible t…”
BackgroundDrug Discovery in a Multidimensional World: Systems, Patterns, and Networks
Dudley, J. T., Schadt, E. E., Sirota, M., Butte, A. J., & Ashley, E. A. (2010) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-010-9214-6 · Cited by 64
The development of label-free cellular assays for drug discovery
Ye, F. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.642360 · Cited by 60
“To improve the efficiency of lead selection process, biological fingerprints based on binding profiles [92], gene expression profiles [93,94], cellular phenotypic effects [95], side effects [96] and chemical structures [97,98] can be produced and used for comparative pharmacology analysis.”
MethodChen, X., Liu, M.-X., Cui, Q., & Yan, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043425 · Cited by 60
“Moreover, the drugtarget interaction prediction methods lay a solid foundation for identifying new indication of approved drugs and hence accelerate new drug development and human medical improvement [9–13].”
MethodChen, H.-R., Sherr, D. H., Hu, Z., & DeLisi, C. (2016) · BMC Medical Genomics · doi:10.1186/s12920-016-0212-7 · Cited by 64
“Sirota, M., et al. [15] searched for drug candidates based on similarities between drug response gene signatures (DEG) and [12] predicted drug molecular functions based on drug response gene signatures.”
BackgroundYosipof, A., Guedes, R. C., & García‐Sosa, A. T. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00162 · Cited by 66
“This implies a specific profile of interaction of a compound (or several compounds) with several targets, such as is the case seen in clinic-approved kinase inhibitors, while at the same time avoiding off-or anti-targets that may be responsible for side-effects (Campillos et al., 2008).”
BackgroundSecondary pharmacology: screening and interpretation of off-target activities – focus on translation
Whitebread, S., Dumotier, B. M., Armstrong, D., Fekete, A., Chen, S., Hartmann, A., Muller, P. Y., & Urbán, L. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.021 · Cited by 60
Dong, J. N., Yao, Z., Wen, M., Zhu, M., Wang, N., Miao, H., Lü, A., Zeng, W., & Cao, D. (2016) · Journal of Cheminformatics · doi:10.1186/s13321-016-0146-2 · Cited by 62
“Campillos et al. proposed a novel method to identify new targets based on the similarity of side effects by Daylight-type topological fingerprints [67].”
MethodSpugnini, E. P., & Fais, S. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.01.003 · Cited by 62
Data Sets Representative of the Structures and Experimental Properties of FDA-Approved Drugs
Douguet, D. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00462 · Cited by 61
Li, L., Zhou, X., Ching, W., & Wang, P. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-501 · Cited by 62
“Significant work [8-11] has been done on drug discovery by integrating different data sources including gene expression data, protein sequence, mass spectrum, chemical structure, drug response and side effects.”
BackgroundDrug-therapy networks and the prediction of novel drug targets
Spiro, Z., Kovacs, I. A., & Csermely, P. (2008) · Journal of Biology · doi:10.1186/jbiol81 · Cited by 56
“[39] published a network of 502 drugs and their side effects using these data to predict novel drug targets based on side-effect similarity of two chemically dissimilar drugs.”
BackgroundA Multilayer Network Approach for Guiding Drug Repositioning in Neglected Diseases
Berenstein, A. J., Magariños, M. P., Chernomoretz, A., & Agüero, F. (2016) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0004300 · Cited by 67
DMAP: a connectivity map database to enable identification of novel drug repositioning candidates
Huang, H., Nguyen, T., Ibrahim, S., Shantharam, S., Yue, Z., & Chen, J. Y. (2015) · BMC Bioinformatics · doi:10.1186/1471-2105-16-s13-s4 · Cited by 55
“If the drug-drug similarity relationships, disease-disease similarity relationships, or side-effect-to-side-effect similarity relationships [7] are characterized, one may populate indications from one drug to another among all drugs under study that are closely related through shared disease,…”
BackgroundThe role of translational bioinformatics in drug discovery
Buchan, N. S., Rajpal, D. K., Webster, Y., Alatorre, C., Gudivada, R. C., Zheng, C., Sanséau, P., & Koehler, J. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.03.002 · Cited by 63
Identification of Similar Binding Sites to Detect Distant Polypharmacology
Jalencas, X., & Mestres, J. (2013) · Molecular Informatics · doi:10.1002/minf.201300082 · Cited by 59
Microfluidic-Based Multi-Organ Platforms for Drug Discovery
Rezaei Kolahchi, A., Khadem Mohtaram, N., Pezeshgi Modarres, H., Mohammadi, M., Geraili, A., Jafari, P., Akbari, M., & Sanati-Nezhad, A. (2016) · Micromachines · doi:10.3390/mi7090162 · Cited by 53
“On the other hand, in the disease-based methods, the clinical perspective or pathology of the disease is considered as in methods using shared molecular pathology [236–239] and side effect similarity [221,240].”
MethodThe human gut chemical landscape predicts microbe-mediated biotransformation of foods and drugs
Guthrie, L., Wolfson, S., & Kelly, L. (2019) · eLife · doi:10.7554/elife.42866 · Cited by 55
“Assessing toxicity similarity Toxicity similarity was computed as described by Campillos and colleagues (Campillos et al., 2008)”
BackgroundMethodBinding site matching in rational drug design: algorithms and applications
Naderi, M., Lemoine, J. M., Govindaraj, R. G., Kana, O. Z., Feinstein, W. P., & Bryliński, M. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bby078 · Cited by 59
“Contrastingly, drug-based techniques initiate the discovery from the chemical perspective, considering similarities among drug molecules [101], target binding sites [102] and side effects [103].”
BackgroundCheng, Y., He, C., Xiao, C., Ding, J., Ren, K., Yu, S., Zhuang, X., & Chen, X. (2013) · Polymer Chemistry · doi:10.1039/c3py00364g · Cited by 55
Yeh, S.-H., Yeh, H., & Soo, V. (2012) · Journal of Clinical Bioinformatics · doi:10.1186/2043-9113-2-1 · Cited by 58
“Systems medicine is an emerging approach in systems biology that aims at integrating a large scale of the molecular interaction data and experimental data to elucidate diseases and drugs associations [4,5].”
BackgroundDrug repositioning through incomplete bi-cliques in an integrated drug–target–disease network
Daminelli, S., Haupt, V. J., Reimann, M., & Schroeder, M. (2012) · Integrative Biology · doi:10.1039/c2ib00154c · Cited by 56
Large-Scale Predictive Drug Safety: From Structural Alerts to Biological Mechanisms
García-Serna, R., Vidal, D., Remez, N., & Mestres, J. (2015) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00260 · Cited by 56
Screening drug-target interactions with positive-unlabeled learning
Peng, L., Zhu, W. Q., Liao, B., Yu, D., Chen, M., Chen, Y., & Yang, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-08079-7 · Cited by 60
del Valle, E. P. G., García, G. L., Santamaría, L. P., Zanin, M., Menasalvas, E., & Rodríguez‐González, A. (2019) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2019.103206 · Cited by 62
In silico drug repositioning: from large-scale transcriptome data to therapeutics
Kwon, O., Kim, W., Cha, H., & Lee, H. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01176-3 · Cited by 59
Sawada, R., Iwata, M., Tabei, Y., Yamato, H., & Yamanishi, Y. (2018) · Scientific Reports · doi:10.1038/s41598-017-18315-9 · Cited by 58
Drug Repurposing - Hypothesis, Molecular Aspects and Therapeutic Applications
Badria, F. A.-E. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.83082 · Cited by 66
Structural basis of efficacy-driven ligand selectivity at GPCRs
Powers, A. S., Pham, V., Burger, W. A. C., Thompson, G. V., Laloudakis, Y. D., Barnes, N. W., Sexton, P. M., Paul, S. M., Christopoulos, A., Thal, D. M., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-022-01247-5 · Cited by 58
Wallach, I., Jaitly, N., & Lilien, R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012063 · Cited by 53
“. Their findings reinforce the hypothesis that structurally similar drugs are likely to induce similar side-effects. Campillos et al. identified alternative targets for known drugs under the hypothesis that structurally similar drugs sharing similar side-effect profiles were also likely to share targets”
Analysis of Chemical and Biological Features Yields Mechanistic Insights into Drug Side Effects
Duran‐Frigola, M., & Aloy, P. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.03.017 · Cited by 58
“This rationale inspired a systematic analysis to identify novel drug-target interactions using SE profiles (Campillos et al., 2008) and has been further reformulated to capture more complex biological entities, such as pathways (Wallach et al., 2010) or cellular processes (Lee et al., 2011).”
MethodOh, M., Ahn, J., & Yoon, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111668 · Cited by 53
“The polypharmacological concept can lead to drug repositioning, which involves finding new indications for existing drugs or side effects due to the molecular mechanisms that may underlie a chemical–disease connection [3,4].”
BackgroundNetwork predicting drug’s anatomical therapeutic chemical code
Wang, Y., Chen, S., Deng, N.-Y., & Wang, Y. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt158 · Cited by 53
Distinctive Behaviors of Druggable Proteins in Cellular Networks
Mitsopoulos, C., Schierz, A. C., Workman, P., & Al-Lazikani, B. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004597 · Cited by 53
Anticipating drug side effects by comparative pharmacology
García-Serna, R., & Mestres, J. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.509343 · Cited by 54
“Consistently performing in vitro safety profiling of hundreds of compounds over multiple targets can be logistically complicated and extremely expensive and thus there is increasing interest in developing in silico methods for the identification of new targets that could explain some of the side effects known for old…”
BackgroundOntologies in Quantitative Biology: A Basis for Comparison, Integration, and Discovery
Jensen, L. J., & Bork, P. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000374 · Cited by 52
“The first links human diseases to animal models through cross-species comparison of phenotypes and anatomical structures [23], and the second identifies hitherto unknown targets for existing drugs by comparing side effects [24].”
BackgroundSelf-citationRelating Anatomical Therapeutic Indications by the Ensemble Similarity of Drug Sets
Wu, L., Ai, N., Liu, Y., Wang, Y., & Fan, X. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400155x · Cited by 55
Chen, B. D., Greenside, P., Paik, H., Sirota, M., Hadley, D., & Butte, A. J. (2015) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12009 · Cited by 51
“Drug side effect similarity has been also employed to predict drug targets.(9) The combination of similarities based on multiple structural, biological, and phenotypic features has led to the discovery of new drug indications.”
BackgroundShaughnessy, A. F. (2011) · BMJ · doi:10.1136/bmj.d741 · Cited by 57
“Another method is to compare side effects of marketed drugs, creating complex networks to discover new receptor targets and pharmacological action. Using algorithms and statistical probability mapping, one approach analysed the likelihood of common targets among 277 885 pairs of 746 marketed drugs. After several nervo…”
BackgroundEXPLORING COMPOUND PROMISCUITY PATTERNS AND MULTI-TARGET ACTIVITY SPACES
Hu, Y., Gupta‐Ostermann, D., & Bajorath, J. (2014) · Computational and Structural Biotechnology Journal · doi:10.5936/csbj.201401003 · Cited by 52
Wang, H., Gu, Q., Wei, J., Cao, Z., & Liu, Q. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.82 · Cited by 51
“We noticed that substantial drug side effect profiles exist in addition to drug indication information that can be explored.(5) So far, this information has not been exploited or properly considered as negative data.”
BackgroundPredicting Drug Side Effects Using Data Analytics and the Integration of Multiple Data Sources
Lee, W., Huang, J.-Y., Chang, H., Lee, K., & Lai, C.-T. (2017) · IEEE Access · doi:10.1109/access.2017.2755045 · Cited by 58
“In fact, other studies have shown that drugs with shared targets, or those close in the interactome network, often share similar side effects [44], [45].”
BackgroundSurvey of Similarity-Based Prediction of Drug-Protein Interactions
Wang, C., & Kurgan, L. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190808154841 · Cited by 52
Boran, A. D. W., & Iyengar, R. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20191 · Cited by 56
Two-stage flux balance analysis of metabolic networks for drug target identification
Li, Z., Wang, R., & Zhang, X. (2011) · BMC Systems Biology · doi:10.1186/1752-0509-5-s1-s11 · Cited by 51
“On the other hand, recent drug research in post-genomic era stresses on the identification of specific biological targets such as enzymes or proteins for drugs, which can be manipulated to produce the desired effect of curing a disease with minimum disruptive side effects [1,4].”
BackgroundRecycling side-effects into clinical markers for drug repositioning
Duran‐Frigola, M., & Aloy, P. (2012) · Genome Medicine · doi:10.1186/gm302 · Cited by 53
“Getting the most out of side-effects Being aware of the efficacy gap between preclinical and clinical outcomes, Bork and collaborators presented, in 2008, a strategy to link precise molecular data with pheno typic observations [7].”
BackgroundMachine learning prediction of side effects for drugs in clinical trials
Galeano, D., & Paccanaro, A. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100358 · Cited by 55
Xu, R., & Wang, Q. (2014) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2014.05.013 · Cited by 49
“It has been increasingly recognized that similar side effects of seemingly unrelated drugs can be caused by their common off-targets and that drugs with similar side effects are likely to share molecular targets [4].”
BackgroundMethodInfluentialTranslational Bioinformatics: Linking the Molecular World to the Clinical World
Altman, R. B. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.49 · Cited by 55
A phenome-guided drug repositioning through a latent variable model
Bişğin, H., Liu, Z., Fang, H., Kelly, R. J., Xu, X., & Tong, W. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-267 · Cited by 53
“Current in silico methodologies in drug repositioning, including phenome-based techniques [17,18], mostly rely on drug-drug similarity measurements which can lead to guilt-by-association [12].”
BackgroundChemogenomic Approaches to Infer Drug–Target Interaction Networks
Yamanishi, Y. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-107-3_9 · Cited by 58
Computational prediction of immune cell cytotoxicity
Schrey, A. K., Nickel-Seeber, J., Drwal, M. N., Zwicker, P., Schultze, N., Haertel, B., & Preißner, R. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.05.041 · Cited by 50
Identifying Unexpected Therapeutic Targets via Chemical-Protein Interactome
Yang, L., Chen, J., Shi, L., Hudock, M. P., Wang, K., & He, L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009568 · Cited by 49
“These unexpected targets could, in some cases, mediate the physiological effect of a drug, even if the drug is designed specifically to target one particular protein [2].”
BackgroundMouse model phenotypes provide information about human drug targets
Hoehndorf, R., Hiebert, T., Hardy, N. W., Schofield, P. N., Gkoutos, G. V., & Dumontier, M. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt613 · Cited by 54
“Received on July 26, 2013; revised on October 2, 2013; accepted on October 18, 2013”
BackgroundPersonalized Cardiovascular Medicine and Drug Development: Time for a New Paradigm
Loscalzo, J. (2012) · Circulation · doi:10.1161/circulationaha.111.089243 · Cited by 51
Emerging Promise of Computational Techniques in Anti-Cancer Research: At a Glance
Rahman, M. M., Islam, M. R., Rahman, F., Rahaman, M. S., Khan, M. S., Abrar, S., Ray, T. K., Uddin, M. B., Kali, M. S. K., Dua, K., et al. (2022) · Bioengineering · doi:10.3390/bioengineering9080335 · Cited by 52
“Phosphatases, transcription factors, and representatives of RAS are categorized as “undruggable” because they require active enzymatic sites [48].”
BackgroundData-Driven Methods to Discover Molecular Determinants of Serious Adverse Drug Events
Chiang, A., & Butte, A. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.274 · Cited by 47
“66 Because similarity in side effects correlated with shared target(s) between drugs, Campillos reasoned that side effect similarity could be used to predict novel targets between any two “unexpected” drug pairs.”
BackgroundMethodInfluentialNatural product mode of action (MOA) studies: a link between natural and synthetic worlds
Clair, J. J. L. (2010) · Natural Product Reports · doi:10.1039/b909989c · Cited by 50
Boland, M. R., Jacunski, A., Lorberbaum, T., Romano, J. D., Moskovitch, R., & Tatonetti, N. P. (2016) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1323 · Cited by 48
“For example, Campillos et al.(36) predicted new drug targets using side effect similarity.”
BackgroundThe Antidepressant-like Effect of Ethanol Extract of Daylily Flowers (金針花 Jīn Zhēn Huā) in Rats
Lin, S.-H., Chang, H.-C., Chen, P.-J., Hsieh, C., Su, K., & Sheen, L. (2013) · Journal of Traditional and Complementary Medicine · doi:10.4103/2225-4110.106548 · Cited by 55
“[12] Although antidepressant may be the most efficient therapy, these drugs will lead to many troublesome side-effects such as nausea, tremor, vomiting, diarrhea, and psychomotor activation.[13-15] Alternatively, several in vitro studies show many natural products having neural protective effect.”
Large-Scale Prediction of Drug-Target Interaction: a Data-Centric Review
Cheng, T., Hao, M., Takeda, T., Bryant, S. H., & Wang, Y. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0092-6 · Cited by 53
“Side effects, or the adverse effects of drugs, contain important clinical phenotypic information that may be useful for predicting novel targets of a drug (61) and have been explored in relating drug-protein interaction network (62).”
BackgroundDrug interaction networks: an introduction to translational and clinical applications
Azuaje, F. J. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs289 · Cited by 50
Xu, R., & Wang, Q. (2015) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2015.03.009 · Cited by 47
“Current systems approaches to studying phenotypic or side effect relationships among drugs rely exclusively on information extracted from the US Food and Drug Administration (FDA) drug labels [17, 18, 19, 20, 21].”
BackgroundLabel-free integrative pharmacology on-target of drugs at the β2-adrenergic receptor
Ferrie, A. M., Sun, H., & Ye, F. (2011) · Scientific Reports · doi:10.1038/srep00033 · Cited by 47
“Before measuring the DMR induced by b-drugs, A431 was preconditioned under eight different conditions: (1) the assay vehicle for 1 hr as a control; (2) 1 mM propranolol (PRO) for 1 hr; (3) 5 nM epinephrine (EPI) for 1 hr; (4) 5 nM EPI for 5 hrs; (5) 400 ng/ml Chorea toxin (CTx) for overnight; (6) 100 ng/ml Pertussis t…”
The impact of network biology in pharmacology and toxicology
Panagiotou, G., & Taboureau, O. (2012) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2012.657237 · Cited by 47
“Connecting drugs by side effect similarity was recently proven to be an attractive strategy to predict novel off-targets involved in the negative clinical outcome of drugs [47,48].”
BackgroundMulti-Omic Data Interpretation to Repurpose Subtype Specific Drug Candidates for Breast Cancer
Turanlı, B., Karagoz, K., Bidkhori, G., Sinha, R., Gatza, M. L., Uhlén, M., Mardinoğlu, A., & Arğa, K. Y. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00420 · Cited by 49
“Module Specific Drug Repositioning To identify small molecules that can potentially reverse gene expression of basal-like tumors, we utilized the Library of Integrated Network-based Cellular Signatures (LINCS) – L1000 data which includes gene expression data from ∼50 human cell line in response to ∼20,000 compounds (C…”
MethodWang, W., Haerian, K., Salmasian, H., Harpaz, R., Chase, H. S., & Friedman, C. (2011) · PubMed Central · Cited by 46
Predictive methods in drug repurposing: gold mine or just a bigger haystack?
Cavalla, D. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.12.009 · Cited by 52
Strategic Applications of Gene Expression: From Drug Discovery/Development to Bedside
Bai, J. P. F., Alekseyenko, A. V., Statnikov, A., Wang, I., & Wong, P. H. (2013) · The AAPS Journal · doi:10.1208/s12248-012-9447-1 · Cited by 52
Drug repurposing for anticancer therapies. A lesson from proton pump inhibitors
Spugnini, E. P., & Fais, S. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1704733 · Cited by 48
Zielinski, D. C., Filipp, F. V., Bordbar, A., Jensen, K., Smith, J. W., Herrgard, M. J., Mo, M. L., & Palsson, B. O. (2015) · Nature Communications · doi:10.1038/ncomms8101 · Cited by 46
Polypharmacology in Drug Development: A Minireview of Current Technologies
Tan, Z., Chaudhai, R., & Zhang, S. (2016) · ChemMedChem · doi:10.1002/cmdc.201600067 · Cited by 49
A comprehensive review of computational techniques for the prediction of drug side effects
Sachdev, K., & Gupta, M. K. (2020) · Drug Development Research · doi:10.1002/ddr.21669 · Cited by 47
“Certain previous studies have depicted that if the drugs cause similar side effects, they have greater chances of interacting with the same protein targets (Campillos et al., 2008).”
BackgroundMethodPerspectives on Drug Repurposing
Schcolnik‐Cabrera, A., Juárez-López, D., & Dueñas‐González, A. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200831141337 · Cited by 47
Metadata
- Authors
- Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P.
- Affiliations
- European Molecular Biology Laboratory (EMBL), Meyerhofstrasse 1, 69117 Heidelberg, Germany.
- Max Delbrück Center (DE)
- Corresponding author
- Kuhn, Michael
- Venue
- Science
- Published
- 2008-07-11
- Volume
- 321
- Issue
- 5886
- Pages
- 263-266
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2154896031
- Cited by
- 1,248
- References
- 27
- Citations by year
- 2026: 21 · 2025: 28 · 2024: 42 · 2023: 35 · 2022: 70 · 2021: 64 · 2020: 73 · 2019: 91 · 2018: 81 · 2017: 67 · 2016: 93 · 2015: 102 · 2014: 92 · 2013: 95 · 2012: 105
- FWCI
- 82.73
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Keywords
- drug target identification, adverse drug reactions, phenotypic similarity, drug repurposing, drug-target interactions, marketed drugs
- MeSH terms
- Algorithms, Chemistry, Pharmaceutical, Drug Labeling, Drug Evaluation, Preclinical, Drug Therapy, Pharmaceutical Preparations, Humans, Probability, Proteins, Databases, Factual, Adverse Drug Reaction Reporting Systems, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.